Evaluation of bis-benzimidazoles in the treatment of murine lymphocytic choriomeningitis virus infections.
Seventy percent of the mice receiving (S,S)-1,2-bis(5-methoxy-2-benzimidazolyl)-1,2-ethandiol (A36683) in their drinking water lived at least four times longer than control mice when infected with 10 or 100 mean lethal doses of lymphocytic choriomeningitis virus strain UBC. In the next 4 months, most of the survivors died with lymphocytic choriomeningitis-like symptoms. Drug treatment during the first 7 days after infection was found to have no significant effect on virus titers in various organs. The sparing effect of the drug is discussed in terms of immunosuppression.
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D005026:Ethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D008216:Lymphocytic Choriomeningitis / Q000188:drug therapy* / Q000382:microbiology; D008217:Lymphocytic choriomeningitis virus / Q000302:isolation & purification; D051379:Mice; D008813:Mice, Inbred ICR; D013997:Time Factors; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D001562:Benzimidazoles; D005026:Ethylene Glycols